The latest price target for Rallybio (NASDAQ:RLYB) was reported by HC Wainwright & Co. on August 12, 2024. The analyst firm set a price target for $6.00 expecting RLYB to rise to within 12 months (a possible 430.97% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Rallybio (NASDAQ:RLYB) was provided by HC Wainwright & Co., and Rallybio maintained their buy rating.

There is no last upgrade for Rallybio

The last downgrade for Rallybio Corp happened on May 15, 2024 when JP Morgan changed their price target from N/A to N/A for Rallybio Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rallybio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rallybio was filed on August 12, 2024 so you should expect the next rating to be made available sometime around August 12, 2025.

While ratings are subjective and will change, the latest Rallybio (RLYB) rating was a maintained with a price target of $9.00 to $6.00. The current price Rallybio (RLYB) is trading at is $1.13, which is out of the analyst’s predicted range.